234 related articles for article (PubMed ID: 23561477)
1. Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
Davila ML; Brentjens R
Hematol Oncol Clin North Am; 2013 Apr; 27(2):341-53. PubMed ID: 23561477
[TBL] [Abstract][Full Text] [Related]
2. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
[TBL] [Abstract][Full Text] [Related]
3. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
Hollyman D; Stefanski J; Przybylowski M; Bartido S; Borquez-Ojeda O; Taylor C; Yeh R; Capacio V; Olszewska M; Hosey J; Sadelain M; Brentjens RJ; Rivière I
J Immunother; 2009; 32(2):169-80. PubMed ID: 19238016
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
5. Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.
Bouhassira DC; Thompson JJ; Davila ML
Expert Opin Biol Ther; 2015 Mar; 15(3):403-16. PubMed ID: 25666545
[TBL] [Abstract][Full Text] [Related]
6. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
7. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
8. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
Oluwole OO; Davila ML
J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
[TBL] [Abstract][Full Text] [Related]
9. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
Mancikova V; Smida M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073911
[TBL] [Abstract][Full Text] [Related]
10. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Halton E; Lamanna N; Rademaker J; Sadelain M; Brentjens RJ; Park JH
Mol Ther; 2018 Aug; 26(8):1896-1905. PubMed ID: 29910179
[TBL] [Abstract][Full Text] [Related]
11. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
Fraietta JA; Schwab RD; Maus MV
Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
[TBL] [Abstract][Full Text] [Related]
12. CARs in chronic lymphocytic leukemia -- ready to drive.
Hosing C; Kebriaei P; Wierda W; Jena B; Cooper LJN; Shpall E
Curr Hematol Malig Rep; 2013 Mar; 8(1):60-70. PubMed ID: 23225251
[TBL] [Abstract][Full Text] [Related]
13. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
Davila ML; Bouhassira DC; Park JH; Curran KJ; Smith EL; Pegram HJ; Brentjens R
Int J Hematol; 2014 Apr; 99(4):361-71. PubMed ID: 24311149
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
16. Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival
Zhang A; Sun Y; Du J; Dong Y; Pang H; Ma L; Si S; Zhang Z; He M; Yue Y; Zhang X; Zhao W; Pi J; Chang M; Wang Q; Zhang Y
Front Immunol; 2021; 12():724211. PubMed ID: 34675920
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
[TBL] [Abstract][Full Text] [Related]
18. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
[TBL] [Abstract][Full Text] [Related]
20. Chasing cancer with chimeric antigen receptor therapy.
Pham CD; Mitchell DA
Immunotherapy; 2012 Apr; 4(4):365-7. PubMed ID: 22512629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
